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ABSTRACT
Objective CHF5633 (Chiesi Farmaceutici S.p.A., Parma, 
Italy) is the first fully synthetic surfactant enriched by 
peptide analogues of two human surfactant proteins. We 
planned to assess safety and tolerability of CHF5633 and 
explore preliminary efficacy.
Design Multicentre cohort study.
Patients Forty infants from 27+0 to 33+6 weeks 
gestation with respiratory distress syndrome requiring 
fraction of inspired oxygen (FiO2) ≥0.35 were treated 
with a single dose of CHF5633 within 48 hours after 
birth. The first 20 received 100 mg/kg and the second 20 
received 200 mg/kg.
Outcome measures Adverse events (AEs) and 
adverse drug reactions (ADRs) were monitored with 
complications of prematurity considered AEs if occurring 
after dosing. Systemic absorption and immunogenicity 
were assessed. Efficacy was assessed by change in FiO2 
after dosing and need for poractant-alfa rescue.
Results Rapid and sustained improvements in FiO2 
were observed in 39 (98%) infants. One responded 
neither to CHF5633 nor two poractant-alfa doses. A total 
of 79 AEs were experienced by 19 infants in the 100 mg/
kg cohort and 53 AEs by 20 infants in the 200 mg/
kg cohort. Most AEs were expected complications 
of prematurity. Two unrelated serious AEs occurred 
in the second cohort. One infant died of necrotising 
enterocolitis and another developed viral bronchiolitis 
after discharge. The single ADR was an episode of 
transient endotracheal tube obstruction following a 
200 mg/kg dose. Neither systemic absorption, nor 
antibody development to either peptide was detected.
Conclusions Both CHF5633 doses were well 
tolerated and showed promising clinical efficacy profile. 
These encouraging data provide a basis for ongoing 
randomised controlled trials.
Trial registration number  ClinicalTrials. gov 
NCT01651637.
InTRODuCTIOn
Respiratory distress syndrome (RDS) remains a 
leading cause of morbidity in preterm babies.1 
Surfactant replacement therapy has become stan-
dard of care in RDS management.2 3 Comparative 
trials show superiority of natural, animal-derived 
surfactants over protein-free synthetic surfactants 
due to the presence of surfactant proteins SP-B 
and SP-C.4A fully synthetic surfactant would have 
potential advantages such as no dependence on 
animal sources and less batch-to-batch variability.5 
Animal experiments suggest that synthetic surfac-
tants containing both peptides are superior to single 
peptide surfactants.6
CHF5633 is a new fully synthetic surfactant 
preparation consisting of phosphatidylcholine 
and phosphatidylglycerol, enriched by peptide 
analogues of both human surfactant proteins SP-B 
and SP-C. When suspended in saline the final 
phospholipid concentration is identical to that of 
poractant-alfa (Curosurf, Chiesi Farmaceutici S. p. 
A., Parma, Italy), at 80 mg/mL and a similar small 
dosing volume can be used. Intratracheal adminis-
tration of CHF5633 to preterm newborn rabbits 
resulted in marked improvement in lung expan-
sion which is no different from poractant-alfa.7 
The structure of the peptide analogues has been 
modified to be resistant to oxidative injury and 
may improve resistance to inactivation.8 9 Preterm 
lambs with RDS treated with CHF5633 have better 
lung and brain injury scores than those treated with 
poractant-alfa.10 Based on these results it was antic-
ipated that CHF5633 would be at least as effective 
as natural surfactants in the treatment of babies 
with RDS.
What is already known on this topic?
 ► Randomised trials have confirmed superiority of 
natural, animal-derived surfactants containing 
proteins, over synthetic surfactants comprised 
of phospholipids alone.
 ► New generation surfactants that contain 
peptides mimicking effects of surfactant 
proteins have shown promise but are not yet 
widely accepted.
What this study adds?
 ► This first–in–human trial of synthetic surfactant 
CHF5633, containing peptide analogues of 
two surfactant proteins, shows that it was well 
tolerated without unexpected adverse effects.
 ► CHF5633 is similar in volume and appearance 
to poractant-alfa and appears to work as 
effectively.
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Surfactant treatment is normally administered as an endo-
tracheal fluid bolus to infants. Conducting a phase I study in 
adults was not appropriate. Accordingly, following consulta-
tion with regulatory agencies and ethics committees, the study 
was designed to recruit premature neonates with ‘mild to 
moderate’ RDS who would be less likely to have other comor-
bidities and who would respond readily to rescue with other 
surfactants, if required.
This study aimed to investigate the safety and tolerability of 
intratracheal administration of CHF5633 in preterm babies. 
Two different doses (100 mg/kg and 200 mg/kg) were evaluated 
in terms of adverse events (AEs), adverse drug reactions (ADRs), 
haematology and biochemistry values, incidence of comorbidi-
ties, extent of systemic exposure to protein analogues and any 
potential immune response. Effects of CHF5633 on oxygen-
ation, ventilatory requirements and need for rescue surfactant 
was assessed to explore efficacy.
MeThODS
This was a first-in-human, single-escalating dose per-cohort 
study on administration of CHF5633. The trial was conducted in 
compliance with the Declaration of Helsinki and current guide-
lines for Good Clinical Practice after approval by regulatory 
authorities in each participating country and the ethical review 
boards for each institution and prior registration ( ClinicalTrials. 
gov NCT01651637). Written consent was sought before birth, 
or soon after, giving parents the maximum time to make an 
informed decision before enrolment.
Infants were eligible within 48 hours after birth if born 
between 27+0 and 33+6 weeks’ gestation, having clinical and 
radiological findings of RDS, and needing fraction of inspired 
oxygen concentration (FiO2) ≥0.35 on continuous positive 
airways pressure (CPAP) to maintain preductal pulse oximeter 
oxygen saturation (SpO2) in the range 90%–95%. They required 
a normal cranial ultrasound scan and their clinician considered 
that surfactant was indicated. Infants were ineligible if they 
had already received surfactant, were already in another study, 
had a major congenital malformation, if there was a history 
of maternal drug/alcohol abuse, a clinical suspicion of pneu-
monia or sepsis, a 5 min Apgar score ≤3, a history of ruptured 
membranes of ≥3 weeks, or if seizures or pneumothoraces were 
detected before enrolment. The study was unusual in recruiting 
infants from whom, albeit for one dose, usual treatment was 
withheld. It was anticipated that a single-centre study would 
be prohibitively slow; therefore 40 babies were enrolled from 
12 centres in three European countries, with careful coordina-
tion to control recruitment. The first infant was treated on 3 
October 2012 and the last completed follow-up on 23 January 
2015.
Two groups of 20 infants were treated. The first cohort was 
given 100 mg/kg of CHF5633 (1.25 mL/kg) and the second 
cohort 200 mg/kg (2.5 mL/kg), administered by bolus via an 
endotracheal tube with a short period of manual/mechan-
ical ventilation. No infant could receive more than one dose 
of CH5633. Failure of response was defined as fall in FiO2 
<0.10 to maintain SpO290%–95% within an hour after treat-
ment. Treatment failures were rescued with either 100 mg/kg or 
200 mg/kg poractant-alfa (Curosurf, Chiesi Farmaceutici, Parma, 
Italy). All infants could receive further doses of poractant-alfa 
as necessary. Decisions around premedication for intubation, 
positioning for surfactant administration, modes and duration 
of ventilatory support as well as weaning protocols were left to 
individual participating centres.
Safety and tolerability
A Safety Monitoring Board (SMB) was established comprising 
the principal investigator from each site and an independent 
neonatologist. The SMB reviewed the safety profile of CHF5633 
in the week following administration and provided authorisation 
to continue. The first four babies in each cohort were recruited 
individually and recruitment stopped until progress to 7 days 
was reviewed. The subsequent 16 babies in each cohort were 
recruited in groups of four before SMB review. Safety and effi-
cacy assessments were performed in the 24 hours following 
CHF5633 administration (at 0.5 hour, 1 hours, 3 hours, 6 hours, 
12 hours and 24 hours), in the following 6 days (at days 2, 3 and 
7) and in the follow-up period (at days 10 and 28, and at 36 
weeks’ postmenstrual age). FiO2, SpO2, ventilator settings and 
blood pressure were monitored. Haematological and biochem-
ical indices were collected at baseline, 24 hours and between 
5 days and 10 days postdose. Data on all predefined expected 
neonatal comorbidities and deviations from expected normal 
values in haematological/biochemical indices were recorded as 
AEs and reviewed by the SMB for expectedness, severity and 
potential relatedness to study medication.
evidence of systemic absorption and immunogenicity
Blood concentrations of SP-B and SP-C analogues were measured 
before, and 3 hours and 24 hours post-treatment using dried 
blood spots. SP-C concentrations were determined using vali-
dated HPLC-MS/MS methods (Accelera, Milan, Italy). Immu-
nogenicity was assessed using 1 mL blood obtained 4–12 weeks 
after CHF5633 administration. IgG antibodies to peptides were 
assayed by titration versus positive control (SGS Life Science 
Services, Wavre, Belgium).
efficacy
Efficacy was evaluated by examining response to CHF5633 in 
terms of changes in SpO2, FiO2, mean airway pressure (MAP), 
peak inspiratory pressure if ventilated and positive end-expira-
tory pressure at specified time points. Duration of mechanical 
ventilation was defined as time until first extubation lasting 
>24 hours. Durations of CPAP and supplemental oxygen were 
recorded. Bronchopulmonary dysplasia (BPD) was defined 
as need for supplemental oxygen to maintain SpO2 ≥90% at 
36 weeks’ postmenstrual age. The number of non-responders 
requiring rescue surfactant was recorded.
Statistical analysis
Because of the exploratory nature of this study, no formal power 
calculation was performed. Twenty babies in each cohort were 
deemed sufficient for reaching useful preliminary conclusions. 
Categorical variables are described using summary statistics, 
frequency count and percentages. Continuous variables are 
summarised using mean, SD, or median, IQR as appropriate.
ReSulTS
A total of 75 babies were consented and 40 were dosed 
between October 2012 and November 2014 (figure 1). Base-
line demographic data are shown in table 1. Date of patient 
recruitment, centre, AEs, and outcomes for each participating 
infant are shown in table 2.
Treatment with either dose of CHF5633 resulted in a rapid 
improvement in oxygenation with corresponding decrease 
in the need for supplemental oxygen and a reduced MAP 
(figure 2). Ten babies were extubated to CPAP immediately 
following CHF5633 administration and never ventilated. A 
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further four were ventilated for <30 min. The median (IQR) 
duration of mechanical ventilation was 0.70 (0.30–0.91) 
days in the 100 mg/kg cohort and 0.30 (0.02–0.95) days in 
the 200 mg/kg cohort. The median (range) duration of CPAP 
was 14.4 (4.9–29.9) days in the 100 mg/kg cohort and 6.7 
(4.0–14.1) in the 200 mg/kg cohort. There was only one case 
of failure to respond to CHF5633, in the first cohort. This 
32-week gestation 1490 g baby was treated at 37 hours of age, 
and had two further 200 mg/kg doses of poractant-alfa, but 
still without improvement in oxygenation. A pneumothorax 
was diagnosed 5 hours after study treatment; this was drained 
and the infant responded to high-frequency oscillation. In 2 of 
the 40 infants a repeat dose of poractant-alfa was required as 
part of ongoing management (table 2). Four babies developed 
BPD, two from each dosing cohort.
Systemic absorption/immunogenicity
No quantifiable concentrations of the SP-C analogue were 
detected in any blood sample at any time point. It was impos-
sible to assess absorption of the SP-B analogue because in 
low quantities it is difficult to measure. No immune response 
antibodies were detected to either peptide from 36 available 
samples.
Figure 1 Patients’ disposition. FiO2, fraction of inspired oxygen; NEC, necrotising enterocolitis; RDS, respiratory distress syndrome.
Table 1 Baseline characteristics
100 mg/kg cohort
(n=20)
200 mg/kg cohort
(n=20)
Gestational age (weeks) 29.6 (2.0) 29.6 (1.9)
Birth weight (g) 1274 (398) 1364 (416)
5 min Apgar 8.5 (8–9.5) 8 (7–8.5)
Gender male 11 (55%) 10 (50%)
Antenatal steroids 18 (90%) 19 (95%)
Antenatal antibiotics 11 (55%) 9 (45%)
FiO2 predose 0.47 (0.16) 0.52 (0.13)
Time to treatment (hours) 7 (4–23) 5 (3–16.5)
Data are shown as mean (SD) and n (%),
Median (IQR) is reported for Apgar score and time to treatment.
FiO2, fraction of inspired oxygen.
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Adverse events
In total, 132 AEs were recorded, 79 experienced by 19 (95%) 
infants in the 100 mg/kg cohort and 53 by 20 (100%) infants in the 
200 mg/kg cohort. Most events were expected clinical problems 
of preterm infants such as mild hyponatraemia. The investigators 
assessed and classified the laboratory values as normal, abnormal/
not significant or abnormal/clinically significant. Most abnor-
malities were assessed as abnormal/not significant. Comorbidi-
ties before and after treatment are summarised in table 3 and are 
typical of issues in preterm babies.
Table 2 Patient sequence, individual characteristics, adverse events and outcomes
Treatment date Country
Age Rx 
(hours) FiO2 Sex BW (g)
GA 
(week)
laboratory 
abnormalites Initial MV CPAP Adverse events
100 mg/kg cohort
  3 October 2012 UK2 2 0.42 M 1505 30 ↓Na ↑SBR 22 hours 6 days
  24 January 2013 UK2 24 0.57 M 1160 31 ↑SBR 5 hours 5 days
  16 February 2013 UK1 5 0.38 F 900 27 ↓Na ↑WCC 3 hours 39 days
  1 March 2013 UK1 4 0.70 M 1660 31 ↑Na ↓K 17 hours 3 days
  19 April 2013 UK1 4 0.40 F 1010 28 ↓Na INSURE 11 days
  26 April 2013 UK1 24 0.45 F 1270 30 None 21 hours none
  21 May 2013 GER8 8 0.44 M 805 28 ↓WCC ↑SBR ↑BG 18 hours 47 days
  11 June 2013 UK1 6 0.40 F 1243 31 ↓Na ↓K INSURE 9 days
  27 June 2013 GER7 15 0.45 F 988 28 ↑SBR 1 day 29 days PDA
  29 June 2013 UK6 4 0.36 M 1100 27 None 6 hours 6 days IVH day 5 PVL day 28.
  8 July 2013 GER10 4 0.40 M 2250 33 ↑SBR 14 hours 2 days
  31 July 2013 UK2 5 0.44 F 1995 32 ↑CRP 17 hours none
  20 September 2013 UK1 9 0.36 F 832 28 ↓Na INSURE 36 days
  22 September 2013 GER10 1 0.35 M 1490 32 None 16 hours 3 days Non-responder, PTX rescue 
Poractant x 2
  18 October 2013 GER8 37 0.45 F 1490 33 ↑HR 4 days 6 days SVT day 20
  6 November 2013 UK1 3 0.68 M 1140 28 ↓Na 8 hours 23 days PDA
  22 November 2013 UK1 41 0.40 M 843 28 ↓Na ↑SBR 3 hours 55 days
  15 December 2013 GER7 24 1.0 M 1371 29 ↑SBR 21 hours 19 days PDA
  8 January 2014 UK1 10 0.36 M 1580 31 ↓Na ↑SBR ↓plats INSURE 8 days
  30 January 2014 UK5 22 0.36 F 850 27 None 10 days 53 days PDA second dose Poractant day 5
200 mg/kg cohort
  21 February 2014 GER7 2 0.50 F 1050 30 ↑SBR 12 hours 3 days Apnoeic episode
  23 March 2014 CZE3 4 0.80 M 1100 27 ↑SBR 10 hours 48 days PDA
  12 April 2014 UK6 4 0.75 M 1685 30 ↓plats 19 hours 13 days
  9 May 2014 CZE4 3 0.50 M 1070 28 ↑SBR INSURE 4 days Apnoeic episode
  26 May 2014 CZE4 26 0.38 F 1800 32 None INSURE 4 days
  27 May 2014 CZE4 20 0.38 F 1075 27 None INSURE 16 days Episode of ET tube blockage, PDA
  1 June 2014 CZE3 2 0.60 F 1590 30 ↑SBR INSURE 5 days
  1 June 2014 CZE3 3 0.40 F 1490 30 ↑SBR INSURE 4 days
  25 June 2014 CZE3 2 0.45 M 1130 28 ↑SBR ↓Na 40 mins 26 days
  26 June 2014 CZE3 25 0.51 M 1060 28 ↑SBR↓Na INSURE 26 days
  27 June 2014 GER10 5 0.60 M 975 28 None 14 hours 12 days PDA, PTX,
second dose Poractant day 2, NEC 
day 13 - died
  28 July 2014 UK 5 0.63 M 1690 33 None 20 hours 1 day
  29 August 2014 UK5 5 0.55 F 870 27 None INSURE 33 days
  15 Septembert 2014 CZE4 33 0.70 F 2080 32 ↑SBR INSURE 4 days
  26 September 2014 UK1 13 0.36 F 876 31 ↑SBR, ↓Na INSURE 8 days
  26 September 2014 CZE3 10 0.50 M 1306 30 None 1 hour 12 days
  21 October 2014 CZE3 2 0.55 M 1720 31 ↑SBR 1 hour 7 days
  11 November 2014 UK1 29 0.41 M 1688 30 None 23 hours 7 days
  18 November 2014 UK6 5 0.48 F 2190 32 None 5 hours 2 days
  21 November 2014 UK5 6 0.41 F 840 28 None 3 days 41 days
↓Na, hyponatraemia; ↓K, hypokalaemia; ↑SBR, hyperbilirubinaemia; ↑WCC, leucocytosis; ↓WCC, leucopenia; ↑BG, hyperglycaemia; ↑CRP, elevated C reactive protein; ↓plats, 
thrombocytopenia; ↑HR, tachycardia; PTX, pneumothorax; IVH, intraventricular haemorrhage; NEC, necrotising enterocolitis; PDA, patent ductus arteriosus; PVL, periventricular 
leucomalacia; SVT, supraventricular tachycardia; Column 2 shows sequence of recruitment by country and site. GER-Germany; CZE-Czech Republic. Site number according to 
instutions of authors. Age Rx, treatment age; FiO2, fraction of inspired oxygen required just prior to dosing; BW, birthweight; GA, gestational age; MV, mechanical ventilation; 
CPAP, continuous positive airways pressure; ET, endotracheal; INSURE, INtubation-SURfactant_Extubation
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Adverse drug reactions
Only one ADR was reported. Following administration of 
200 mg/kg to a 27+2 week, 1075 g infant there was temporary 
obstruction of the endotracheal tube for 10–15 s, which resolved 
quickly with no clinical consequences. The baby was extubated 
after 4 min, with a transient rise in FiO2 to 80% but reducing 
over the following 3 hours on CPAP, and had echocardiographic 
evidence of transient pulmonary hypertension. Neither allergic 
reactions, nor any other events potentially caused by the drug, 
were reported.
Serious adverse events
Two SAEs were reported, both occurring in the 200 mg/
kg cohort: an episode of fulminant necrotising enterocolitis 
occurring 13 days after CHF5633 in an infant of 28 weeks’ 
gestation who died at 21 days, and an episode of postdischarge 
viral bronchiolitis considered as serious due to need for rehos-
pitalisation. Neither SAE was considered related to the study 
drug.
DISCuSSIOn
This first-in-human study shows that a CHF5633 dose of either 
100 mg/kg or 200 mg/kg was well tolerated, without detect-
able systemic absorption, and resulted in prompt and sustained 
improvements in respiratory function. CHF5633 is the first 
synthetic surfactant to contain analogues of both SP-B and SP-C. 
It was developed to be similar to poractant-alfa (Curosurf) in 
terms of its low dose volume, appearance and simple handling 
requirements. It requires refrigeration, and only a short period 
of warming in the hand prior to administration, and the volume 
to deliver a 200 mg/kg dose is 2.5 mL/kg. Following a single 
intratracheal dose the brisk response allowed rapid extubation, 
including the use of the INtubation-SURfactant-Extubation 
(INSURE) approach that is widely used with animal-derived 
surfactants.11 Apart from one patient, all infants showed an 
immediate clinical response with a single dose.
The population selected for this study was reasonably stable 
babies with RDS, deliberately chosen because of the relatively 
low risk of complications to allow an informative safety and 
tolerability assessment. They required surfactant, but were not 
so unwell that there was insufficient time to obtain consent and 
baseline investigations. Most were stable on CPAP, but with 
increasing oxygen requirements. Such babies are scarce, there-
fore recruitment at multiple sites was needed to achieve the 
required study population, even though this would be consid-
ered unusual for a phase I trial. The initial requirement to halt 
after each enrolled subject made recruitment slow.
Despite careful selection of subjects, the majority still devel-
oped a range of comorbidities that needed to be analysed within 
the context of what would normally be expected in a preterm 
baby requiring surfactant. Only one death occurred; a case of 
NEC considered a consequence of prematurity and unrelated 
to CHF5633 treatment. The single episode of transient tube 
obstruction was also considered a well recognised complication 
of surfactant therapy. Neither allergic reactions nor other events 
likely caused by the drug were reported. Lack of systemic expo-
sure and of specific immune response was also reassuring. The 
overall rate of mortality, BPD, and their combination was low as 
would be expected with this selected, relatively low-risk, preterm 
population.12 These data are promising and randomised controlled 
trials should now determine how CHF5633 performs in a larger 
population including less mature and sicker infants ( ClinTrials. gov 
NCT02452476).
Baseline characteristics were similar in the two dosing cohorts, 
although the predose FiO2 and MAP were slightly higher in 
the second cohort, perhaps reflecting increasing confidence at 
recruiting sicker babies. Statistical comparisons were not made 
between dosing cohorts for this reason. Both doses were effica-
cious, resulting in sustained improvements in oxygenation that 
occurred immediately after instillation. A median FiO2 of 0.21 
was achieved within the first 24 hours of treatment. In terms of 
respiratory support, a shorter duration of non-invasive venti-
lation was found in the 200 mg/kg cohort despite them being 
slightly worse at baseline. This might reflect a greater improve-
ment of lung mechanics with higher doses of CHF5633, although 
this needs to be tested in randomised trials.
Only one other protein-containing synthetic surfactant, luci-
nactant, had reached the stage of being used in comparative 
clinical trials in preterm neonates.13 14 Lucinactant contains a 
high concentration of the synthetic peptide sinapultide (KL-4), 
designed to have similar activity to SP-B, but no SP-C peptide. 
Lucinactant is a viscous fluid requiring warming to 44°C then 
vigorous shaking until it becomes a free-flowing suspension. 
Figure 2 Fraction of inspired oxygen (FiO2) in all babies and 
corresponding mean airway pressure (MAP) in those undergoing 
mechanical ventilation 24 hours after CHF5633 in the two dosing 
cohorts. Bars represent SD. Data offset slightly to improve clarity. Inset 
shows same data over first 3 hours to illustrate speed of onset of action 
of effect.
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The approved treatment dose volume is 5.8 mL/kg. In contrast, 
CHF5633 is more akin to poractant-alfa in terms of its handling 
requirements and the observed clinical response parallels that 
observed in trials of existing animal-derived surfactants.15 16
Current thinking about optimal management of RDS is to aim 
where possible to avoid mechanical ventilation.17 Administering 
surfactant without mechanical ventilation is gaining acceptance 
as a strategy to minimise lung injury.18 19 Fourteen babies in this 
study were extubated within 30 min of CHF5633 administration, 
including 10 where clinicians employed the INSURE technique. 
Future comparative trials of CHF5633 should therefore explore 
all potential modes of administration including minimally invasive 
methods.
Animal-derived surfactants require pooling of material from 
multiple animals. Quality control is stringent, but many stake-
holders would be reassured if the theoretical risks of infection 
could be avoided. There is a drive towards ensuring that children of 
all ages have access to age-appropriate formulations. This involves 
tailoring administration to the needs of the child and optimising 
pharmaceutical quality of the product. By ensuring that the volume 
to be administered is small and avoiding use of animal products, the 
development of CHF5633 addresses these needs. Ideally it would 
also prove to be more efficacious in some circumstances. Studies 
in a sheep model of acute lung injury suggest that CHF5633 may 
be more resistant to inactivation than poractant-alfa.20 This raises 
the possibility that it may have advantages in severe disease, or 
in other causes of respiratory failure associated with surfactant 
inhibition.21–24
In conclusion, CHF5633 is the first synthetic surfactant to 
contain analogues to both surfactant proteins, SP-B and SP-C. 
This first-in-human study shows that it was well tolerated 
by preterm babies with moderate RDS and raised no safety 
concerns, with a promising clinical efficacy profile. Larger trials 
are warranted and if these produce similar results it is likely that 
this will herald a new era of synthetic surfactant treatment.
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Table 3 Comorbidities and complications of prematurity
100 mg/kg cohort (n=20) 200 mg/kg cohort (n=20)
Before n (%) After n (%) Before n (%) After n (%)
Any comorbidity 5 (25) 15 (75) 2 (10) 13 (65)
Anaemia 0 0 1 (5) 0
Tachycardia 1 (5) 0 0 0
Patent ductus arteriosus 1 (5) 4 (20) 0 2 (10)
Bacterial sepsis 1 (5) 1 (5) 0 0
Sepsis unspecified 0 1 (5) 0 2 (10)
Low fibrinogen 0 0 1 (5) 0
Hyperglycaemia 1 (5) 2 (10) 0 0
Hypoglycaemia 1 (5) 1 (5) 1 (5) 0
Hypoalbuminaemia 0 0 1 (5) 0
Hyponatraemia 1 (5) 8 (40) 0 3 (15)
Necrotising enterocolitis 0 1 (5) 0 1 (5)
Hyperbilirubinaemia 0 5 (25) 0 10 (50)
Intraventricular haemorrhage 0 1 (5) 0 0
Cerebral haemorrhage 0 1 (5) 0 0
Periventricular leukomalacia 0 1 (5) 0 0
Bronchopulmonary dysplasia NA 2 (10) NA 2 (10)
Pneumothorax 0 1 (5) 0 1 (5)
Pulmonary interstitial emphysema 0 0 0 1 (5)
 NA, not applicable.
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